Alexandre Mérieux, Chairman and Chief Executive Officer, said: "All told, 2017 was a year of remarkable growth for bioMérieux, driven by a portfolio of complementary technological solutions and a broad geographic footprint. We are particularly pleased with the performance of BIOFIRE, which confirms the success of syndromic diagnosis for infectious diseases, and with the faster-paced growth in industrial applications. These results reflect a valid business strategy that meets the needs of healthcare professionals through high medical value diagnostic solutions, and of the industry sector in order to protect consumer’s health."
Marcy l'Étoile, January 23, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the twelve months ended December 31, 2017.